mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma

BACKGROUND: Systemic therapy has proven only marginal effects in hepatocellular carcinoma (HCC) so far. The aim of this study was to evaluate the effect of targeting fibroblast growth factor receptor (FGFR) on tumour and stromal cells in HCC models. METHODS: Human and murine HCC cells, endothelial c...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheller, T, Hellerbrand, C, Moser, C, Schmidt, K, Kroemer, A, Brunner, S M, Schlitt, H J, Geissler, E K, Lang, S A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453944/
https://www.ncbi.nlm.nih.gov/pubmed/25688743
http://dx.doi.org/10.1038/bjc.2014.638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453944/
https://www.ncbi.nlm.nih.gov/pubmed/25688743
http://dx.doi.org/10.1038/bjc.2014.638

Ejemplares similares